Emerging markets have heated up for every industry, but the world's biggest pharmaceutical players have approached the challenges of capturing these promising markets in unique ways. Generic competition spawned by loose legal frameworks and a lack of solid middle-class wealth has hampered big pharma's push into some of the world's top developing economies, but the industry's top companies can't afford to miss out on this hundred-billion dollar opportunity in the making.
Sales around the pharmaceutical industry have been falling because of patent losses, and untapped emerging markets represent one last low-hanging frontier for the sector. Can big pharma take advantage of the world's fast-growing developing nations -- and are China, India, and other emerging economies even ready for the industry's entrance? Motley Fool contributor Dan Carroll and health care analyst Max Macaluso discuss below what you need to know about big pharma's battle to win the emerging markets.
Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, The Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.